DK1280552T3 - Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor - Google Patents

Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor

Info

Publication number
DK1280552T3
DK1280552T3 DK00946969T DK00946969T DK1280552T3 DK 1280552 T3 DK1280552 T3 DK 1280552T3 DK 00946969 T DK00946969 T DK 00946969T DK 00946969 T DK00946969 T DK 00946969T DK 1280552 T3 DK1280552 T3 DK 1280552T3
Authority
DK
Denmark
Prior art keywords
endothelin
compositions
skin cancer
receptor inhibitor
treating skin
Prior art date
Application number
DK00946969T
Other languages
Danish (da)
English (en)
Inventor
Paul H Patterson
Coutre-Lahav Ronit Le
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Application granted granted Critical
Publication of DK1280552T3 publication Critical patent/DK1280552T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00946969T 1999-06-29 2000-06-29 Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor DK1280552T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14145099P 1999-06-29 1999-06-29
US09/404,626 US6545048B1 (en) 1999-06-29 1999-09-23 Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
PCT/US2000/018215 WO2001000198A2 (fr) 1999-06-29 2000-06-29 Compositions et procede de traitement du cancer avec des compositions contenant un inhibiteur de l'activite du recepteur de l'endotheline

Publications (1)

Publication Number Publication Date
DK1280552T3 true DK1280552T3 (da) 2008-01-07

Family

ID=26839135

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00946969T DK1280552T3 (da) 1999-06-29 2000-06-29 Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor

Country Status (11)

Country Link
US (1) US6545048B1 (fr)
EP (1) EP1280552B1 (fr)
AT (1) ATE369871T1 (fr)
AU (1) AU6065000A (fr)
CA (1) CA2376912A1 (fr)
CY (1) CY1108778T1 (fr)
DE (1) DE60036025T2 (fr)
DK (1) DK1280552T3 (fr)
ES (1) ES2292454T3 (fr)
PT (1) PT1280552E (fr)
WO (1) WO2001000198A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3050424B2 (ja) * 1991-07-12 2000-06-12 塩野義製薬株式会社 ヒトエンドセリンリセプター
US7566452B1 (en) * 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
WO2002062989A2 (fr) * 2001-02-08 2002-08-15 Sequitur, Inc. Procedes de liberation activee par la lumiere de ligands a partir d'endosomes
WO2003006041A1 (fr) * 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
CA2463816C (fr) 2001-10-19 2014-07-08 Vascular Biogenics Ltd. Constructions de polynucleotides, compositions pharmaceutiques et procedes de regulation negative de l'angiogenese et de therapie anticancereuse
ATE493126T1 (de) 2001-11-01 2011-01-15 Spectrum Pharmaceuticals Inc Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
EP2213737B1 (fr) 2002-02-01 2012-11-07 Life Technologies Corporation Oligonucleotides double brin
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
JP2006508086A (ja) * 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
EP1526380A1 (fr) * 2003-10-21 2005-04-27 Progenika Biopharma, S.A. Méthode de diagnostic in vitro et de pronostic in vitro du cancer du pancréas et méthode pour le développement de médicaments contre le cancer du pancréas
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2005101013A2 (fr) * 2004-04-15 2005-10-27 Reglia Ab Substances et procedes pour le criblage de modulateurs de la regeneration neuronale
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
ATE495752T1 (de) 2005-07-19 2011-02-15 Population Council Inc Verfahren und zusammensetzungen zur notfallbedingten verhütung mithilfe von endothelin-rezeptor-antagonisten
EP2059254B1 (fr) 2006-08-31 2015-04-08 Spectrum Pharmaceuticals, Inc. Sensibilisation de cellules tumorales à la radiothérapie par administration d'agonistes d'endothéline
US9289426B2 (en) * 2007-03-21 2016-03-22 University Of Pennsylvania Methods and compositions for treating solid tumors and enhancing tumor vaccines
US20100204149A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of octreotide as a therapeutic agent
US20090205661A1 (en) * 2008-02-20 2009-08-20 Nellcor Puritan Bennett Llc Systems and methods for extended volume range ventilation
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
TWI429453B (zh) * 2010-02-23 2014-03-11 建南德克公司 抗tat419抗體及其用途
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
CA2879665A1 (fr) 2012-08-02 2014-02-06 Genentech, Inc. Anticorps et immunoconjugues anti-etbr
MX2015001407A (es) 2012-08-02 2015-05-08 Genentech Inc Inmunoconjugados y anticuerpos anti-etbr.
AU2014287427B2 (en) 2013-07-08 2019-11-21 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist
US10695400B2 (en) 2015-08-03 2020-06-30 Enb Therapeutics, Inc. Compositions and methods for treating cancers associated with ETBR activation
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
CN114423425A (zh) * 2019-07-17 2022-04-29 Enb治疗公司 通过使用内皮素b受体拮抗剂治疗尿路上皮癌和肾癌

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US6030975A (en) 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer

Also Published As

Publication number Publication date
CA2376912A1 (fr) 2001-01-04
DE60036025D1 (de) 2007-09-27
ATE369871T1 (de) 2007-09-15
WO2001000198A2 (fr) 2001-01-04
EP1280552B1 (fr) 2007-08-15
PT1280552E (pt) 2007-11-23
AU6065000A (en) 2001-01-31
CY1108778T1 (el) 2014-04-09
WO2001000198A3 (fr) 2002-10-31
DE60036025T2 (de) 2008-04-30
US6545048B1 (en) 2003-04-08
ES2292454T3 (es) 2008-03-16
EP1280552A2 (fr) 2003-02-05

Similar Documents

Publication Publication Date Title
DK1280552T3 (da) Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
DE60005017D1 (de) Prodrugs von impdh-inhibierenden carbamaten
MY121548A (en) Compounds and methods for the treatment of cancer
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ES2158115T3 (es) Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas.
AU2209800A (en) Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE69924500D1 (de) Chinazolinderivate
ATE339957T1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE602005019010D1 (de) Verwendung eines Extraktes aus Angelica sinensis als Wachstumsinhibitor von Krebszellen in der Tumortherapie
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
ATE327973T1 (de) Polyamin-analoge als cytotoxische wirkstoffe
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen